drugset / Trial / NCT05288855

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

NCT05288855

Phase 3 Terminated 9 enrolled Aurinia Pharmaceuticals Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of voclosporin compared to placebo in achieving renal response following 24 weeks of therapy in adolescent and pediatric subjects with active lupus nephritis (LN).

Timeline

Start
2023-10-10
Primary completion
2025-07-03
Completion
2025-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Voclosporin Other / unclassified 15.8 mg
Subject Voclosporin Other / unclassified 23.7 mg

Indications